Apr 01, 2021 / 04:30PM GMT
Paul Andrew Matteis - Stifel, Nicolaus & Company, Incorporated, Research Division - Co-Head of the Biotech Team, MD & Senior Analyst
Great. Thanks very much. It's my pleasure to be hosting a panel that can trend spotlight and talk about different assets within Neurocrine's pipeline with Neurocrine's Chief Medical Officer, Eiry Roberts; and Chief Business Development Officer, Kyle Gano. So thank you both for joining and always enjoy doing the panel with the 2 of you.
I think maybe to start, I don't know, Eiry, if you'd like to make any kind of opening remarks on some of your R&D programs that you're going to have data soon. And feel free to do so, or if not, we can just kind of go 1 by 1 and as you know, I have questions on each. So up to you, but thank you again.
Eiry Wyn Roberts - Neurocrine Biosciences, Inc. - Chief Medical Officer
Yes. Well, thanks very much, Paul. It's great to be here, and hi to everybody. We're delighted to be here. Thanks to Stifel for inviting us today. Just wanted to start really and we can then get straight into
Neurocrine Biosciences Inc at Stifel CNS Day Transcript
Apr 01, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers